Tags

Type your tag names separated by a space and hit enter

Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study--the Hjørring project.
Acta Obstet Gynecol Scand Suppl. 1984; 123:177-84.AO

Abstract

Thirty premenopausal women with recurrent, pronounced cyclical mastodynia associated with mammographically confirmed fibrocystic disease were studied. All patients had long-standing symptoms, had undergone one previous course of treatment with danazol, and were recruited during long-term follow-up after original treatment, when cyclical mastodynia had again reached similar severity as before the original treatment (mean interval between treatments 9.5 +/- 3.9 (SD) months). Fifteen patients each were randomly allocated to double-blind treatment with either danazol or placebo. During the first month, 2 capsules a day (each containing danazol 100 mg or placebo) were given, thereafter one capsule a day up to 6 months. Danazol caused a marked and sustained decrease in mastodynia, according to the clinician's assessment and according to each patient's self-rating on a visual analogue scale. The response to danazol was fairly uniform and statistically significant (p less than 0.005 or less), whereas the response to placebo was inconsistent and not statistically significant (p greater than 0.10). Danazol proved significantly more effective than placebo (p less than 0.05 or less). Changes in palpatory and/or mammographic findings were also found more consistently after danazol treatment than after placebo. During treatment, there was a modest weight increase, which was statistically significant in the danazol group (p less than 0.01) but not in the placebo group. A greater frequency in menstrual irregularities was observed in the danazol group than in the placebo group, but not to an extent that would have caused 'unblinding' of the study.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

6388218

Citation

Döberl, A, et al. "Treatment of Recurrent Cyclical Mastodynia in Patients With Fibrocystic Breast Disease. a Double-blind Placebo-controlled Study--the Hjørring Project." Acta Obstetricia Et Gynecologica Scandinavica. Supplement, vol. 123, 1984, pp. 177-84.
Döberl A, Tobiassen T, Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study--the Hjørring project. Acta Obstet Gynecol Scand Suppl. 1984;123:177-84.
Döberl, A., Tobiassen, T., & Rasmussen, T. (1984). Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study--the Hjørring project. Acta Obstetricia Et Gynecologica Scandinavica. Supplement, 123, 177-84.
Döberl A, Tobiassen T, Rasmussen T. Treatment of Recurrent Cyclical Mastodynia in Patients With Fibrocystic Breast Disease. a Double-blind Placebo-controlled Study--the Hjørring Project. Acta Obstet Gynecol Scand Suppl. 1984;123:177-84. PubMed PMID: 6388218.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double-blind placebo-controlled study--the Hjørring project. AU - Döberl,A, AU - Tobiassen,T, AU - Rasmussen,T, PY - 1984/1/1/pubmed PY - 1984/1/1/medline PY - 1984/1/1/entrez SP - 177 EP - 84 JF - Acta obstetricia et gynecologica Scandinavica. Supplement JO - Acta Obstet Gynecol Scand Suppl VL - 123 N2 - Thirty premenopausal women with recurrent, pronounced cyclical mastodynia associated with mammographically confirmed fibrocystic disease were studied. All patients had long-standing symptoms, had undergone one previous course of treatment with danazol, and were recruited during long-term follow-up after original treatment, when cyclical mastodynia had again reached similar severity as before the original treatment (mean interval between treatments 9.5 +/- 3.9 (SD) months). Fifteen patients each were randomly allocated to double-blind treatment with either danazol or placebo. During the first month, 2 capsules a day (each containing danazol 100 mg or placebo) were given, thereafter one capsule a day up to 6 months. Danazol caused a marked and sustained decrease in mastodynia, according to the clinician's assessment and according to each patient's self-rating on a visual analogue scale. The response to danazol was fairly uniform and statistically significant (p less than 0.005 or less), whereas the response to placebo was inconsistent and not statistically significant (p greater than 0.10). Danazol proved significantly more effective than placebo (p less than 0.05 or less). Changes in palpatory and/or mammographic findings were also found more consistently after danazol treatment than after placebo. During treatment, there was a modest weight increase, which was statistically significant in the danazol group (p less than 0.01) but not in the placebo group. A greater frequency in menstrual irregularities was observed in the danazol group than in the placebo group, but not to an extent that would have caused 'unblinding' of the study.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0300-8835 UR - https://www.unboundmedicine.com/medline/citation/6388218/Treatment_of_recurrent_cyclical_mastodynia_in_patients_with_fibrocystic_breast_disease__A_double_blind_placebo_controlled_study__the_Hjørring_project_ L2 - https://medlineplus.gov/pain.html DB - PRIME DP - Unbound Medicine ER -